Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.

Patient-derived xenografts chemotherapy mucinous ovarian cancer

Journal

American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944

Informations de publication

Date de publication:
2020
Historique:
received: 25 10 2019
accepted: 05 11 2019
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 21 3 2020
Statut: epublish

Résumé

Mucinous ovarian carcinoma (mEOC) represents a rare subtype of epithelial ovarian cancer, accounting for 3-4% of all ovarian carcinomas. The rarity of this tumor type renders both the preclinical and clinical research compelling. Very few preclinical

Identifiants

pubmed: 32195028
pmc: PMC7061742

Types de publication

Journal Article

Langues

eng

Pagination

572-580

Informations de copyright

AJCR Copyright © 2020.

Déclaration de conflit d'intérêts

None.

Références

Oncotarget. 2017 Jan 31;8(5):7441-7451
pubmed: 26910918
Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57
pubmed: 27141073
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Hematol Oncol Clin North Am. 2018 Dec;32(6):1011-1024
pubmed: 30390757
Virchows Arch. 2019 Mar;474(3):289-296
pubmed: 30631934
Cancer Sci. 2009 Mar;100(3):546-51
pubmed: 19154404
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Cancer Lett. 2017 Feb 1;386:100-109
pubmed: 27864115
Int J Gynecol Cancer. 2015 Mar;25(3):372-9
pubmed: 25514350
BMC Cancer. 2015 May 19;15:415
pubmed: 25986173
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
Mol Cancer Ther. 2019 Jan;18(1):162-172
pubmed: 30305341
Br J Haematol. 2013 Aug;162(4):566-9
pubmed: 23692203
Exp Mol Pathol. 2013 Oct;95(2):235-41
pubmed: 23965232
Clin Cancer Res. 2012 Oct 1;18(19):5267-77
pubmed: 22891197
Int J Cancer. 1989 Sep 15;44(3):494-500
pubmed: 2777413
Cancer Res. 2014 Dec 1;74(23):6980-90
pubmed: 25304260
Genome Med. 2015 Aug 07;7(1):87
pubmed: 26257827
Sci Rep. 2016 Jun 22;6:28398
pubmed: 27329432
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29795040
Front Oncol. 2016 Sep 30;6:205
pubmed: 27747192
Crit Rev Oncol Hematol. 2016 Jun;102:26-36
pubmed: 27083591
J Clin Oncol. 2004 Mar 15;22(6):1040-4
pubmed: 15020606
Cell Cycle. 2012 May 15;11(10):1966-76
pubmed: 22544328
Ann Oncol. 2017 Apr 1;28(4):718-726
pubmed: 27993794
Br J Cancer. 2006 Mar 27;94(6):904-13
pubmed: 16508639
Int J Gynecol Pathol. 2004 Jan;23(1):41-4
pubmed: 14668549
J Ovarian Res. 2018 Oct 30;11(1):91
pubmed: 30376858
Nat Med. 2019 May;25(5):838-849
pubmed: 31011202
Hum Genomics. 2016 Dec 28;10(1):40
pubmed: 28031051
Gynecol Oncol. 2018 Jul;150(1):127-135
pubmed: 29793804

Auteurs

Francesca Ricci (F)

Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Federica Guffanti (F)

Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Roberta Affatato (R)

Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Laura Brunelli (L)

Protein and Gene Biomarkers Unit, Laboratory of Mass Spectrometry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Pastorelli Roberta (P)

Protein and Gene Biomarkers Unit, Laboratory of Mass Spectrometry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Robert Fruscio (R)

Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, San Gerardo Hospital, University of Milan Bicocca Monza 20900, Italy.

Patrizia Perego (P)

Clinic of Obstetrics and Gynecology, San Gerardo Hospital Monza 20900, Italy.

Maria Rosa Bani (MR)

Laboratory of Laboratory of Biology and Treatment of Metastasis, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Giovanna Chiorino (G)

Cancer Genomics Laboratory, Fondazione Edo and Elvo Tempia Biella, Italy.

Andrea Rinaldi (A)

Institute of Oncology Research, Università della Svizzera italiana Bellinzona 6500, Switzerland.

Francesco Bertoni (F)

Institute of Oncology Research, Università della Svizzera italiana Bellinzona 6500, Switzerland.

Maddalena Fratelli (M)

Laboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Giovanna Damia (G)

Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan 20156, Italy.

Classifications MeSH